Vibegron
Brand names: Gemtesa
At a glance
- Medicare prescriptions, 2024
- 1,184,653
- Medicare drug cost
- $804.2M
- Average cost per prescription
- $679
- Clinicians who prescribed it
- 20,517
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
GEMTESA is a beta-3 adrenergic agonist indicated for the treatment of: overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH).
From the FDA-approved prescribing information (label dated March 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Urology 34.5%
- Nurse Practitioners 20.9%
- Physician Assistants 11.5%
- Internal Medicine 10.4%
- Family Medicine 8.7%
- Urogynecology 7.4%
- OB-GYN (Obstetrics & Gynecology) 2.4%
- Geriatric Medicine 1.6%
- General Practice 0.5%
- Hospitalist 0.4%
- Emergency Medicine 0.3%
- Nephrology (Kidney) 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2021–2024
Medicare prescriptions rose 2,584% from 2021 to 2024.
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Sumitomo Pharma America, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 75 mg | green oval tablet, 9 mm | V75 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $2.0M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Sumitomo Pharma America, Inc. $2.0M
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Industry-funded trials
- Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC Recruiting · Sumitomo Pharma America, Inc.
- Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB) Completed · Sumitomo Pharma America, Inc.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.